Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence
Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence
复制标题
DOI：
10.1016/s0022-5347(05)65387-6
复制
发表时间：
2002-01-01
影响因子：
6.6
通讯作者：
Holmäng, S
中科院分区：
文献类型：
--
作者：
Boman, H;Hedelin, H;Holmäng, S
目的：检测尿中3种膀胱癌标志物的敏感性和特异性，包括NMP22检测(马萨诸塞州牛顿)、BTA STAT检测(Bion诊断科学公司，华盛顿州雷德蒙德)和UBC抗原(IDL Biotech，瑞典索伦图纳)，以及膀胱冲洗细胞学对新发和复发膀胱癌的诊断价值。我们检查肿瘤的大小、分级和分期是否影响标记物的敏感性和特异性。材料和方法：250名患者的304个样本被研究。174例患者有膀胱癌病史，其中93例膀胱镜检查有肿瘤复发，81例无复发。另一组患者包括66例新诊断的膀胱肿瘤患者，检查镜下血尿，发现是特发性血尿。根据制造商的说明进行BTA STAT的检测。采用酶联免疫吸附试验检测尿液中NMP22和UBC的含量。以NMP22和LTBC为界值分别为4和1，以获得与BTA STAT(75%)相同的特异度。
Purpose: We determine the sensitivity and specificity of 3 bladder tumor markers in urine, including NMP22 assay (Matritech, Newton, Massachusetts), BTA stat test (Bion Diagnostic Sciences, Inc., Redmond, Washington) and UBC antigen (IDL Biotech, Sollentuna, Sweden), and bladder wash cytology for new and recurrent bladder cancer. We examine whether tumor size, grade, and stage influence sensitivity and specificity of the markers.Materials and Methods: A total of 304 samples in 250 patients were studied. There were 174 patients who had a history of bladder cancer, including 93 with and 81 without recurrent tumor at cystoscopy. The other group of patients consisted of 66 with newly diagnosed bladder tumor and 64 investigated for microscopic hematuria that was found to be idiopathic. BTA stat was assayed according to manufacturer instructions. NMP22 and UBC were measured in urine with an enzyme-linked immunosorbent assay. A cutoff level of 4 for NMP22 and 1 for LTBC was chosen to get the same specificity for new tumors as BTA stat (75%)Results: There was a highly significant difference (p